UnknownPhase 2NCT05738057

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hua Li
Principal Investigator
Yang Yang, MD&PhD
Third Affiliated Hospital, Sun Yat-Sen University
Intervention
Camrelizumab(drug)
Enrollment
22 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05738057 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials